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INTRODUCTION
Exact staging of cervical carcinoma is essential in selecting the most favorable therapy. In the widely used International Federation of Gynecology and Obstetrics (FIGO) stag-
ing system there are significant inaccuracies. With a 24%–39% error rate in gynecologic
examinations also the degree of the pelvic invasion is often inadequately evaluated without 
cross-sectional diagnostic imaging (1-4). Furthermore, lesion volumes, nodal, and distant 
metastases are not assessed. The broad scale of imaging modalities evolved during the last 
two decades contributes to a better knowledge and management of the disease. Magnetic 
resonance imaging (MRI) is now widely accepted as optimal for evaluation of the main
prognostic factors and selection of therapeutic strategy (5-7).
In advanced disease or when bad prognostic factors are present, the complex oncologi-
cal treatment is based on the combination of external irradiation and brachytherapy with 
concomitant chemotherapy. Nevertheless, optimal protocol for the determination of the 
proper therapeutic plan remains to be defined. An unified technique to solve the problems 
connected to precise definition of the gross tumor volume (GTV) and the clinical target 
volume (CTV) with their geometrical change during the external irradiation as well as 
their dose covering during conformal HDR brachytherapy is nowadays becoming widely 
available (8). Reproducibility of the treatment plan along with a stable multiple exact 
repositioning of the patient and the treatment device is essential for the clinical outcome 
of the treatment.
PATIENTS AND METHODS
Patient selection
Between April 2002 and February 2004, 31 patients with locally advanced uterine cervical 
cancer (International Federation of Gynecology and Obstetrics (FIGO) stage distribution: 
IIb-IVa) completed combined external beam radiotherapy (EBRT) and brachytherapy exclu-
sively or in conjunction with concomitant chemotherapy. 
Radiotherapy
For the period of the prospective study a standard radiotherapy treatment protocol was applied con-
taining CT based shrinking volume conformal EBRT, and MRI-assisted brachytherapy with a special 
adjustable applicator. Three-dimensional conformal radiation treatment planning and delivery was 
used for the radiotherapy with the general purpose of shaping the prescribed dose volume to the 
form of the 3-dimensional target volume, simultaneously limiting dose to critical normal structures. 
Initially a CT-image based, planning target volume (PTV) was treated with a four-field box technique 
of EBRT on a Mevatron Primus 15 MV linear accelerator (Siemens, Erlangan, Germany). After 
EBRT with a median dose of 50.6 (range 48.8 – 54.2) Gy in 26 (range: 25 – 28) fractions over 4–5 
weeks to the PTV, the radiation dose was boosted to 61.4 (range 59.8 – 65) Gy.
After the completion of the boost EBRT, a flexible 5 F (1.65 mm) interstitial cervical 
applicator (Cook® BFCS-6.OR-30-STB-25, Bloomington, USA) insertion and fixation were 
performed. The technique and its benefits for the patient and the radiation oncologist had 
been described in details in a previous study (9). 
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ABSTRACT
Background: The aim of this study was to analyze the use of magnetic resonance imaging (MRI) as a 
modern medical imaging technique in radiotherapy with special emphasis on the integration of MRI and 
a novel technique in brachytherapy to optimize treatment outcome in cervical cancer.
Methods: In addition to the CT based shrinking volume conformal teletherapy in 31 patients with locally 
advanced cervical cancer, MRI examination with a special adjustable applicator at the treatment site was 
performed for the brachytherapy planning. To avoid excessive doses to the healthy structures during 
complex cervical radiotherapy isodose curves were calculated upon the information of the MR image 
and dose distribution was evaluated.
Results: The consecutive application of CT and MRI limited the possibility for overdosage of the critical 
organs and undertreatment of the advanced tumor spread in all cases. The overall response rate for 
the complex treatment was 74.2% with complete regression in 25.8% of the cases. Based on the exact 
information of the three dimensional digital data radiation doses could be optimized without increasing 
the possibility of acute complications rate.
Conclusion: The introduction of 3D treatment planning for teletherapy pelvic and boost irradiation of 
cervical carcinoma as well as for the brachytherapy part of the complex treatment is to be recom-
mended.
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MRI
High-resolution T2-weighted fast-spin-echo (TE 95.0, TR 4800.0, FOV 28) MR images (5-mm 
section thickness) (512x512 matrix) were obtained in sagittal and axial planes from the prom-
ontorium to the vulva with the applicator and the patient in the treatment position (Figure 1).
Figure 1. (A) T2 weighted MR images in axial plane from different levels, with the patient and the applica-
tor device in treatment position. The applicator geometry is accurately visualized as well as the surround-
ing tissue and the cervical cancer extension. (B) T2 weighted MR images in sagittal plane, with the patient 
and the applicator device in treatment position. CTV and the organs at risk are delineated on all planes
Decreased imaging time and increased image resolution proved to be an advantage of the 
body coil in combination with fast spin-echo T2-weighted imaging technique, without loss 
of staging accuracy. 
In cases of pelvic soft-tissue edema a fat-saturated T2-weighted sequence was used. This 
sequence often did not demonstrate sufficient contrast between the lesion and the intact 
part of the gynecologic organs and the visualization of the applicator was difficult. Still in 
the cases mentioned above, it proved to be the most-suitable for the differentiation of the 
tumor spread to the surrounding tissue.
When a histologically verified cervical lesion was not clearly detectable on the T2-weighted 
images additional 6 mm slice thickness dynamic gadolinium-enhanced, fat suppression T1 
imaging (TE 11.0, TR 734.0, FOV 200) was used for the evaluation and contouring (Figure 2). 
Complete disruption of the stromal ring with nodular or irregular signal intensity extending into 
the parametrium was taken for a still present invasion.
Figure 2. Gadolinium-enhanced fat-saturated T1-weighted axial cross-section. Spread of tumor tissue 
to the vagina (arrows) and parametrium is well depicted (arrow heads)
During the delineation of the CTV a contour disruption of the vaginal wall with hyperintense
thickening on the T2-weighted images, or contrast material enhancement on the T1-
weighted imaging were considered as signs of vaginal invasion.
Clinical findings for the exact estimation of the vaginal extension were compared to the MRI 
findings and also taken in consideration.
Treatment planning
Sequential MR images were used in delineation of the CTV for the BT and the organs at risk 
(OARs) on all planes. The contour was individually tailored taking into concern the MRI-
defined GTV, where the density of the cancer cells is the highest and the initial, pretreatment 
tumor extension (Figure 1). 
Three dimensional reconstruction and rotation of the structures delineated on the MR 
images facilitated better visualization of the volumes as well as the relationship between the 
organs and the applicator device (Figure 3). 
A conformal BT plan was calculated with the AbacusTM dose-planning system (MDS 
Nordion®, Quebec, Canada). The generated isodose lines and CTV contours were super-
imposed for each axial MR image and were also reconstructed in the sagittal and coronal 
views to visualize the 3D coverage (Figure 4). Dose adaptation to the CTV was based on 
the volumetric measurements for the GTV and the critical organs. Dose volume histograms 
were calculated to evaluate the dose that covers 100% and 90% of the target volume and 
doses to specific absolute volumes of organs at risk. The limits defined for the OARs (rec-
tum and bladder) were 4 Gy per fraction for tissue volume of 2 and 4 cm3, respectively.
Treatment
With the application of the MRI determination of the rectal reference point was done slightly differ-
ently from the recommendation of International Commission on Radiation Units and Measurement 
(ICRU) Report 38 (10). The possible need for a revision of the report written in 1985, due to the 
dramatic progress in imaging, planning and therapy equipment availability, was already raised by 
Pötter and al in 2001(11). The maximum rectal dose was calculated at the points in the anterior 
wall of the rectum closest to the applicator and receiving the maximum dose.
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Figure 3. 3D reconstruction of MR images. The cylindrical holder (transparent dark green) with the 
central and circumferential applicators (light green), the CTV (yellow), the uterus and the OARs; the 
rectum and the bladder (dark-red, brown and orange respectively), and the bone structures (gray) are 
presented. Rotation facilitates better visualization of the volumes as well as the relationship between 
the structures and the applicator device
Figure 4. MR-assisted 3D treatment plan. (A) Three dimensional volumetric representation the 
???????????????????????????????????????????????????????????????????????????????????????????????????
surface). (B) The CTV and the OARs are presented with the isodose coverage on a sagittally and axially 
opened 3D reconstruction
Change of cervix and upper vagina anatomy during the course of the treatment reported 
in the literature was not taken in consideration for the HDR ICB as all the treatments were 
individually planned and performed in a short time interval after the greater volumetric 
change caused by the EBRT (12,13).
The high-dose-rate (HDR) intracavital BT was carried out with a GammaMedplusTM remote 
after-loading machine (Varian Medical Systems Inc. Palo Alto, USA), with 192Ir stepping 
sources. With the aim to improve the local control rate with fewer complications the 
brachytherapy was performed in three fractions, twice a week, with a total dose of 12 Gy 
?????????????? ???????????????
The overall duration of treatment ranged from 50 to 62 days (median, 54 days).
RESULTS
The application of MRI limited the possibility for overdosage of the critical organs and 
undertreatment of the advanced tumor spread in all cases. The spatial relationship of the 
tumor to the bladder, rectum, bowel, applicators, etc. was depicted well. Doses to the tumor 
and surrounding normal tissues were read from isodose curves superimposed on the T2-
weighted sagittal image, which was useful in customizing the dose distribution (Figure 5). 
Figure 5. MRI-based conformal HDR BT plan. T2 weighted axial MR image with the applicator in treat-
ment position and the prescribed fraction isodose curves for 2, 4 and 8 Gy. The delineations of the CTV 
(blue dots) and the OARs; the rectum and the bladder on the sectional images are imported directly into 
the treatment planning system, and the dose-volume association is evaluated. 
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In this manner a reduction of the treated volume could be achieved leading to a possible 
further decrease of complications. In majority of the treatments, rectum and bladder doses 
were less than 70% of target dose due to the rapid fall-off of the brachytherapy dose and 
the conformal visualization provided by the MRI. However on very few treatment plans, in 
order to obtain sufficient covering of the CTV the bladder dose was higher than the required. 
In those cases, the vaginal holder of the applicator device was reseated for better tolerance 
of late responding normal tissues. Dose calculations were checked with an independent 
calculation method and agreement was obtained within 5-7% discrepancy. 
As primary end points, the coverage of the PTVs and the CTV, the dose to the OARs, the 
acute toxicity and CT examination was performed for the local tumor control evaluation. 
Acute adverse events were graded on the basis of Common Terminology Criteria of Adverse 
Events Version 3.0 (CTCAE). The overall response was determined by the Response 
Evaluation Criteria in Solid Tumors (RECIST) guidelines (14).
The treatment proved feasible and was tolerated well by all patients. There was no treatment 
related death. Grade 1 adverse events were evaluated with some difficulties because of the 
minor degree of symptoms, as well as because of the fact that they mostly depended on 
subjective perception. As adverse events evaluation forms were filled in by the patients 
before initiation of the treatment some of the events proved to be preexisting. In those cases 
only the rise of complaints was taken in consideration. Grade 1 diarrhea (with occasional 
abdominal pain) occurred in 6 patients (36%) during the 4th week of the EBRT. Following a 
decrease of the daily dose and a strict adherence to the proposed diet, the clinical signs had 
disappeared by 1 week after the completion of the irradiation. The occurrence of bladder 
complications was less frequent (3 patients, 18%), but more severe (Grade 2; acute sterile 
cystitis with bladder spasm), in the last week of the EBRT. Antibiotics, antispasmolytic 
treatment and an extensive daily fluid intake led to normalization of the patients’ condition. 
Insertional or acute complications related to the BT were not observed.
In acceptance with the RECIST guidelines no non-target lesions were found during the 
baseline documentation and no novel tumorous lesion appeared during the course of 
the treatment. From this respect the overall tumor response to the complex oncological 
treatment was identical with the response of the target lesion. Applying the linear-qua-
dratic model for sublethal damage repair (tumor ???=10, OAR ???=3) the dose of the 
brachyterapy treatment was biologically normalized to the EBRT dose fractions. The PTV, 
PTV-boost and CTV median coverage was 97.4 %, 98.8% and 93.2% respectively. Thus, 
the prescribed total dose, calculated from the parameters of the two irradiation modalities 
was received by 17.7% and 13.3% of the total volume of the OARs’ (the rectum and the 
bladder respectively). Both the coverage of the PTVs and the CTV and the radiation burden 
on the OARs were within acceptable limits.
The posttreatment CT examination and the gynecological physical examination used as 
evaluations for local tumor control showed overall response rate for the complex treatment 
as 74.2%. Clinical results were; complete regression in 8 (25.8%), and partial regression 
in other 15 patients (48.4%). In 7 cases (22.6%), a moderate treatment response was 
achieved, where the disease was considered stable, and poor in 1 patient (3.2%), who 
displayed progression of the disease. 
DISCUSSION
Tumor stage, tumor size and nodal status are the most important prognostic factors in 
cervical cancer. Anteroposterior tumor diameter predominantly affected the incidence of 
distant metastasis, and lymph node status affected both pelvic control and distant metas-
tasis. Since 1984 when Bies and his coworkers published their experience in comparison 
of clinical staging with the CT, MR and surgical findings in gynecological tumors magnetic 
resonance imaging plays a more and more important role in the accurate staging of cervical 
malignancies (15).
With a prospective study it was shown that endosonography and MRI are more accurate 
than CT in the local staging (16). MRI-based diagnosis enables the determination of a 
correct tumor staging preoperatively, and is therefore very helpful in planning an adequate 
therapy. With MRI excellent imaging of the tumor spread within the cervix can be achieved, 
as well as also tumor extension to the parametrium and infiltration of the neighboring struc-
tures (17-19). To date MRI is the method of choice in the preoperative staging of cervical 
cancer and if used more widely it would contribute to simplification and shortening of the 
preoperative diagnostic procedure in patients with cervical carcinoma (19).
Over the last 15 years, treatment of cervical cancer has become increasingly sophisticated 
with advances in external beam and brachytherapy in the radiotherapeutic management of 
this carcinoma. 
Treatment for cancer of the uterine cervix, prior to 1998 originally planned upon radio-
graphic evaluation proved to be insufficient in the knowledge of to what extent the treated 
volume encompasses the CTV and studies came into view with CT-based treatment plan-
ning (20,21). The radiography based planning provides only dimensions and doses at 
selected points, which are difficult to be uniformly defined and exactly reproduced. Even 
when used in combination with physical pelvic examination this technique in spite of its 
cost-effectiveness and convenience, seems nowadays not acceptable. 
Beside the reported high percentage accuracy of MR imaging in staging of cervical 
carcinoma the modality has a great importance in the treatment of cervical cancer (22). 
Regarding therapy the role of MRI may be classified in three main groups; 1) guided appli-
cator positioning; 2) assisted treatment planning and; 3) treatment quality control.
MR imaging provides three-dimensional (3D) anatomic information with capability of 
three-dimensional measurement and has great advantages in terms of soft-tissue contrast 
resolution. The subdivision of different approaches and the transfer from point doses to vol-
umes in treatment planning is possible and practical for the treatment of cervix carcinoma 
in brachytherapy. At the same time MRI is the only imaging modality giving the opportunity 
for an accurate judgment of the invasion towards the surrounding normal tissue. Thus MRI 
based planning provides proper information on target and organ volumes and dose-volume 
histograms.
Since Schoeppel published in 1992 his experience in three patients with MRI during gyne-
cological brachytherapy treatment the need for integration of the two techniques became 
essential (23). Data for conformal brachytherapy dose prescription and treatment planning 
found in the literature still lag behind the state-of-the-art for EBRT. Tardivon and his group 
found MR imaging useful in controlling the relationships between the tumor and the applica-
tor as well as it facilitated treatment planning, since the radiation dose to the tumor volume 
and adjacent critical organs could be calculated accurately with no false-negative results 
observed (24). The comparative use of the MRI for the 3D brachytherapy planning system, 
with the applicators on site, allows dose escalation in the GTV required for the effective 
radiation treatment with maximal protection of the surrounding healthy tissues.
Together with the use of MRI assisted planning for brachytherapy a crucial need for an 
improvement in the applicator technique appeared. The following conditions and terms had 
to be available: 1) the applicator had to be MR-compatible and visible on MRI, CT and X-ray 
screen and film; 2) thin diameter was crucial as the applicator had to be suitable for insertion 
through the cervical channel narrowed by the tumor mass; 3) adequate dosage was needed 
in the cases, when tumor extension involves the mid and lower vaginal mucosa; 4) during the 
gauze packing of the ovoids, either operator error or narrowing of the vaginal apex could result 
in mal-alignment of the colpostats and subsequent inadequate dosing to the exo-cervix. 
The vaginal cylinder used in our study has been designed to address these concerns being 
equipped with the circumferential holes.
The presented technique gives also an opportunity for a MRI guided conversion of intra-
cavitary BT to interstitial BT by means of a simple change of the applicators located in 
circumferential channels of the adjustable vaginal cylinder holder to MR-compatible needles 
(Figure 6). This may be of appreciable importance in patients with disease that cannot be 
optimally encompassed by intracavitary BT in order to achieve more accurate volume 
optimization of dose distribution.
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Figure 6. (A) The intracervical applicator introduced through the central channel of the cylindrical 
holder used for vaginal interposition. (B) The applicator device with MR compatible needles in the 
circumferential channels
There is a belief that it is unnecessary to calculate doses for each HDR insertion beyond the 
first one. This conviction is based mainly on the fixed geometry applicator. It has been shown 
even though the applicator may have reproducible geometry, that it is difficult to insert the 
applicator reproducibly from one insertion to another (25). It is generally supposed that all 
insertions are geometrically identical to the first, so dosimetric errors at one or more of the 
dose points for subsequent insertions may be significant. This dose specification method 
results in underdosing of important target tissues or overdosing of adjacent dose-limiting 
structures (26). On the other hand the ovoid sources of the frequently used applicators do not 
always contribute to local control, and occasionally lead to rectal complications (27). Thus 
optimization of brachytherapy depends on patients’ anatomy, tumor size, and tumor response. 
The single insertion, the fixation to the cervix and the MRI assistance allows a proper volu-
metric dose-planning lowering the possibility for those dosimetric errors. Evaluation of dose-
volume histograms of critical organs and tumor within the reference isodose volumes could 
be performed using MRI assisted three-dimensional planning and computed dosimetry.
The rectal and bladder reference points may not represent the points of maximum dose 
delivery to these organs. Without the use of cross-sectional image assistance, despite the 
determination of multiple reference points this information is inadequate to predict doses 
to the entire rectum and bladder, since single point measurements at the bladder neck seri-
ously underestimate the dose to the bladder. Dose-volume histogram already established 
as a gold-standard in the EBRT is giving a precise dose evaluation of the OARs. Together 
with the better interpretation of target delineation, delineation of critical structures as well as 
dose distribution conformal brachytherapy treatment planning for interstitial brachytherapy 
means significant advantage for the clinical routine compared to 2D or semi-3D methods. 
Cross-sectional image assisted brachytherapy may be inadequately criticized for being a time 
consuming process with high costs. In those institutes, where the MRI based treatment planning 
has been systematically introduced into daily clinical practice and is routinely used, planning proce-
dures on both 2D (semi-3D) and 3D planning systems have a similar time consumption (28,29).
CONCLUSION
Fractionated high dose rate brachytherapy can be given with both higher dosimetric accu-
racy and more adequate irradiation of the tumor component, if it is MRI-assisted and with 
a single applicator insertion. With this new applicator, it was possible to accumulate very 
accurate and detailed 3D dose-distribution data for the critical structures and other points 
of interest in the vicinity of the applicator. These data makes possible the not only the practi-
cal transfer from point doses to volumes in treatment planning, but will permit also future 
analysis of the correlation of dose and outcome for carcinoma of the cervix.
The increase of the therapeutic window by the systematic integration of the MRI into treat-
ment planning, allows it to be highly individualized and with the use of MR-compatible, 
adjustable applicator allows safe and reproducible cervical radiotherapy with no added 
discomfort or hazard for the patient.
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